Read the latest medical research on healthy bone and spine development. Find out about spinal problems and new treatment options.

The status has been given to the B7-H3-targeted drug as a treatment for late-line relapsed or refractory osteosarcoma, a rare form of bone cancer with no FDA-approved treatments.